

# UCSF

## UC San Francisco Previously Published Works

### Title

Metagenomic Shotgun Sequencing of Endocervical, Vaginal, and Rectal Samples among Fijian Women with and without Chlamydia trachomatis Reveals Disparate Microbial Populations and Function across Anatomic Sites: a Pilot Study

### Permalink

<https://escholarship.org/uc/item/1zj8567p>

### Journal

Microbiology Spectrum, 10(3)

### ISSN

2165-0497

### Authors

Bommana, Sankhya  
Richards, Gracie  
Kama, Mike  
[et al.](#)

### Publication Date

2022-06-29

### DOI

10.1128/spectrum.00105-22

Peer reviewed



# Metagenomic Shotgun Sequencing of Endocervical, Vaginal, and Rectal Samples among Fijian Women with and without *Chlamydia trachomatis* Reveals Disparate Microbial Populations and Function across Anatomic Sites: a Pilot Study

 Sankhya Bommana,<sup>a</sup> Gracie Richards,<sup>a</sup> Mike Kama,<sup>b</sup> Reshma Kodimerla,<sup>a</sup> Kenan Jijakli,<sup>c</sup>  Timothy D. Read,<sup>c</sup>  Deborah Dean<sup>a,d,e,f,g</sup>

<sup>a</sup>Department of Pediatrics, University of California San Francisco, Oakland, California, USA

<sup>b</sup>Ministry of Health and Medical Services, Suva, Fiji

<sup>c</sup>Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

<sup>d</sup>Department of Medicine, University of California San Francisco, San Francisco, California, USA

<sup>e</sup>Department of Bioengineering, Joint Graduate Program, University of California San Francisco and University of California Berkeley, San Francisco, California, USA

<sup>f</sup>Bixby Center for Global Reproductive Health, University of California San Francisco, San Francisco, California, USA

<sup>g</sup>Benioff Center for Microbiome Medicine, University of California San Francisco, San Francisco, California, USA

Timothy D. Read and Deborah Dean contributed equally to this article. Author order was determined on the basis of seniority.

**ABSTRACT** *Chlamydia trachomatis* is a sexually transmitted pathogen and a global public health concern. Little is known about the microbial composition and function across endocervical, vaginal, and rectal microbiomes in the context of *C. trachomatis* infection. We evaluated the microbiomes of 10 age-matched high-risk Fijian women with and without *C. trachomatis* using metagenomic shotgun sequencing (MSS). *Lactobacillus iners* and *Lactobacillus crispatus* dominated the vagina and endocervix of uninfected women. Species often found in higher relative abundance in bacterial vaginosis (BV)—*Mageeibacillus indolicus*, *Prevotella* spp., *Sneathia* spp., *Gardnerella vaginalis*, and *Veillonellaceae* spp.—were dominant in *C. trachomatis*-infected women. This combination of BV pathogens was unique to Pacific Islanders compared to previously studied groups. The *C. trachomatis*-infected endocervix had a higher diversity of microbiota and microbial profiles that were somewhat different from those of the vagina. However, community state type III (CST-III) and CST-IV predominated, reflecting pathogenic microbiota regardless of *C. trachomatis* infection status. Rectal microbiomes were dominated by *Prevotella* and *Bacteroides*, although four women had unique microbiomes with *Gardnerella*, *Akkermansia*, *Bifidobacterium*, and *Brachyspira*. A high level of microbial similarity across microbiomes in two *C. trachomatis*-infected women suggested intragenitoretal transmission. A number of metabolic pathways in the endocervix, driven by BV pathogens and *C. trachomatis* to meet nutritional requirements for survival/growth, 5-fold higher than that in the vagina indicated that endocervical microbial functions are likely more diverse and complex than those in the vagina. Our novel findings provide the impetus for larger prospective studies to interrogate microbial/microbiome interactions that promote *C. trachomatis* infection and better define the unique genitoretal microbiomes of Pacific Islanders.

**IMPORTANCE** *Chlamydia trachomatis* is the primary cause of bacterial sexually transmitted infections worldwide, with a disturbing increase in annual rates. While there is a plethora of data on healthy and pathogenic vaginal microbiomes—defining microbial profiles and associations with sexually transmitted infections (STIs)—far fewer studies have similarly examined the endocervix or rectum. Further, vulnerable populations, such as Pacific Islanders, remain underrepresented in research. We investigated the microbial composition, structure, and function of these anatomic microbiomes using metagenomic shotgun

**Editor** Salika M. Shakir, University of Utah and ARUP Laboratories

**Copyright** © 2022 Bommana et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Deborah Dean, [deborah.dean@ucsf.edu](mailto:deborah.dean@ucsf.edu).

The authors declare no conflict of interest.

**Received** 30 January 2022

**Accepted** 20 April 2022

**Published** 17 May 2022

sequencing among a Fijian cohort. We found, primarily among *C. trachomatis*-infected women, unique microbial profiles in endocervical, vaginal, and rectal microbiomes with an increased diversity and more complex microbial pathways in endocervical than vaginal microbiomes. Similarities in microbiome composition across sites for some women suggested intragenitoretal transmission. These novel insights into genitoretal microbiomes and their purported function require prospective studies to better define Pacific Islander microbiomes and microbial/microbiome interactions that promote *C. trachomatis* infection.

**KEYWORDS** *Chlamydia trachomatis*, endocervical microbiome, metabolomics, metagenomic shotgun sequencing, rectal microbiome, sexually transmitted infections, vaginal microbiome, pathogenesis

**C** *hlamydia trachomatis* sexually transmitted infections (STIs) pose a major public health concern due to escalating infections with global estimates of over 130 million cases per year (1). In the United States alone, 1.8 million *C. trachomatis* STIs were reported in 2019, a 19% increase from 2015 (2). However, Pacific Island Countries and Territories (PICT) have the highest prevalence of *C. trachomatis* STIs in the world (3–6), a likely consequence of the poor sensitivity and specificity of syndromic management (i.e., based on signs and symptoms) that have resulted in the undertreatment of *C. trachomatis* STIs (6, 7). Our recent study in Fiji found that *C. trachomatis* STIs occur at hyperendemic levels (30.5%) among adolescent and young adult women who are primarily asymptomatic (6). These untreated STIs can lead to severe inflammatory-related sequelae, such as pelvic inflammatory disease, tubal factor infertility, and preterm birth (8, 9).

*C. trachomatis* can influence the vaginal microbiomes causing diseases such as bacterial vaginosis (BV) (10–12). BV is also a risk factor for acquisition of *C. trachomatis* and other STIs such as *Neisseria gonorrhoeae* and HIV (13). Using 16S rRNA sequencing, previous studies have developed and utilized vaginal bacterial community state types (CSTs) to better understand the susceptibility to STIs. CST-I, CST-II, CST-III, and CST-V are dominated by *Lactobacillus crispatus*, *Lactobacillus gasseri*, *Lactobacillus iners*, or *Lactobacillus jensenii*, which produce lactic acid, bacteriocins, hydrogen peroxide, and other antimicrobial compounds to protect against STIs (14). CST-IV is deficient in *Lactobacillus* spp. with higher proportions of anaerobic bacteria such as *Prevotella bivia*, *Dialister*, *Atopobium vaginae*, *Gardnerella vaginalis*, *Megasphaera elsdenii*, *Peptoniphilus*, *Sneathia*, *Eggerthella*, *Aerococcus*, *Fingoldia*, and *Mobiluncus* (15, 16). This shift from a dominant *Lactobacillus* species population to a diverse microbial state, even when *L. iners* is abundant, is what can lead to acquisition of *C. trachomatis* and other STIs (13, 17).

The characterization of vaginal microbiomes has largely been based on 16S rRNA sequencing that provides genus-level taxonomic profiles of a community (10–12). This is less robust than metagenomic shotgun sequencing (MSS) where DNA is extracted from the entire microbial population, providing unbiased identification of all taxonomic communities of DNA organisms (e.g., fungi, bacteria, DNA viruses, and protozoa) to the species level and often the strain level. Metabolic pathway genes can also be ascertained directly using MSS. More recent studies have used MSS to elucidate vaginal microbial communities, providing examples of the power of this approach (18–20). Although interrogating vaginal microbial communities is important in understanding healthy versus pathogenic microbial environments and risk for STIs, evaluating the endocervix may be more pivotal, as it is the actual site of *C. trachomatis* infection, not the vagina. Very few studies have examined cervical microbiomes used 16S rRNA sequencing in the presence or absence of *C. trachomatis* without comparison to vaginal microbiota (21–24). Only one study to date has evaluated the interrelationship of these microbiomes, again using 16S rRNA sequencing, with a focus on adolescents in South Africa (11). Differences in microbial taxa and diversity were evident between sites, but no significant microbial associations with *C. trachomatis* were found (11).

Numerous studies have now shown that *C. trachomatis* rectal infections outnumber those in the female urogenital tract. In a Dutch study, over 70% of women with urogenital *C. trachomatis* also had rectal *C. trachomatis* (25). There are also reports of rectal *C. trachomatis* infections in the absence of urogenital STIs, suggesting a silent reservoir for transmission (25, 26). Additionally, men who have sex with men (MSM) and women also have high rates of *C. trachomatis* rectal infections (25, 27, 28). Since these infections require a longer treatment regimen of 7 to 21 days compared to a single dose of azithromycin for uncomplicated urogenital infections, there is an increased risk of transmission from ineffective therapy (29, 30). Further, we know relatively little about the interactions of rectal, vaginal, and endocervical microbiomes in transmission and maintenance of infection and disease. Most of what we know about the impact of STIs on rectal microbiomes is from HIV-1 studies (31–34). Currently, few studies have addressed *C. trachomatis* infections and their effect on rectal microbiota (22, 35).

While many studies have evaluated vaginal and gut microbiomes in various populations, these studies have primarily been based on 16S rRNA sequencing (36), and none have explored the microbial composition of the endocervix, vagina, and rectum within or across women or in the context of *C. trachomatis* infection. Here, using a small cohort of age-matched Fijian women with and without *C. trachomatis* infection, we employed MSS to evaluate the microbial composition and relative abundance of microbiota at each site, including concordance/discordance of endocervical, vaginal, and rectal microbiota and the extent and functional significance of microbial sharing across anatomic sites.

## RESULTS

**Patient and sample characteristics.** Table 1 shows the characteristics of the age-matched cohort. The *ompA* genotype, which identifies the *C. trachomatis* strain, was derived from the respective *C. trachomatis* genome sequences (Tim Read, personal communication) (37). The *C. trachomatis* and beta-actin genome copy numbers and chlamydial load for each anatomic site are also shown. The chlamydial mean load was significantly higher in rectal ( $30.36 \pm 20.71$ ) than vaginal sites ( $1.72 \pm 1.77$ ;  $P = 0.0105$ ; one-way analysis of variance [ANOVA]) and in rectal than endocervical sites ( $0.15 \pm 0.05$ ;  $P = 0.0108$ ; one-way ANOVA) (Table 1) in samples from our cohort. Sample 362R was an exception to this, with a higher load detected in the vagina. Sexually transmitted and genitorectal pathogens were considered to be present in the samples if they were detected at a ratio of at least one read per million (RPM; see Materials and Methods) and if the reads corresponded to at least three different regions of the genome. Pathogen reads were confirmed by BLASTn as described by Babiker et al. (see Table S1 in the supplemental material) (38). While all vaginal and endocervical samples were negative for *N. gonorrhoeae* by the Xpert CT/NG test and for human papillomavirus (HPV) by pap smear, respectively, MSS detected five women with rectal *N. gonorrhoeae* infections and two women with HPV infections where the aforementioned tests were not available (Table 1; Table S1). *Candida* was detected by wet prep for sample 319V, while MSS additionally identified *Candida* in one vaginal and one rectal sample. Six women had BV based on Amsel criteria from the parent study; four of these women were infected with *C. trachomatis*, *Mycoplasma genitalium*, or HPV. *M. genitalium* was detected based solely on MSS reads (Table S1). All reads were extracted and confirmed by BLASTn (Fig. 1).

**MSS.** The 30 metagenomes yielded a total of ~2.8 billion raw reads, of which 1.1 billion (39%) were identified as human and removed (Table S2). The reads per sample ranged from 60.66 million to 117.44 million. Comparing human DNA contamination across anatomic sites, we found that there was a significant difference in human to raw read ratio in the rectum versus in the vagina ( $P < 0.0001$ , one-way ANOVA) and in the rectum versus in the endocervix ( $P < 0.0001$ , one-way ANOVA), with a higher mean proportion of human sequence reads in the rectum of 66% (range of 32.4% to 87.6%) than in the endocervix, 24.5%, and in the vagina, 23.6% (range of 8.9% to 48.5%) (Table S2, Fig. S1).


**TABLE 1** Characteristics of age-matched Pacific Islander women of iTaukei ethnicity with and without *C. trachomatis* infection, including *ompA* genotype and load<sup>a</sup>

No.	ID <sup>b</sup>	Status of:						<i>ompA</i> genotype	Age in yrs <sup>e</sup>	<i>C. trachomatis ompA</i> (genomes/ $\mu$ L)	Beta-actin (genomes/ $\mu$ L)	Load <sup>f</sup>
		<i>C. trachomatis</i> status	BV <sup>c</sup>	<i>N. gonorrhoeae</i>	<i>Candida</i>	HPV/type <sup>d</sup>	<i>M. genitalium</i>					
1	72V	+	+	—	—	—	—	G	32	2,107.5	482.5	4.36
2	72R	+	—	—	—	—	+	G		1,664	41.29	40.29
3	72C	+	—	—	—	—	—	G		349.2	2,495.27	0.13
4	98V	+	+	—	—	—	—	G	22	344	3,947.59	0.08
5	98R	+	—	+	—	—	+	G		31,549	555.29	56.81
6	98C	+	—	—	—	—	—	G		434.4	1,809.35	0.24
7	107V	+	+	—	—	—	+	Ja	29	2,218	1,301.54	1.70
8	107R	+	—	—	—	—	+	Ja		18,377	708.58	25.93
9	107C	+	—	—	—	—	+	Ja		21.2	815.62	0.14
10	192V	+	—	—	—	<b>+/7</b>	+	Ja	25	328	2,383.45	0.13
11	192R	+	—	+	—	<b>+/53, 54</b>	+	Ja		43,905	1,550.32	28.31
12	192C	+	—	—	—	—	+	Ja		275.1	NA	NA
13	362V	+	—	—	—	—	—	F	34	1,933.7	829.48	2.33
14	362R	+	—	—	—	+	+	F		576.3	1,236.35	0.46
15	362C	+	—	—	—	—	—	F		136.4	1,067.45	0.12
16	57V	—	+	—	—	—	—	NA	32	NA	NA	NA
17	57R	—	—	—	—	—	+	NA		NA	NA	NA
18	57C	—	—	—	—	—	+	NA		NA	NA	NA
19	35V	—	+	—	—	<b>+/6b, 16</b>	—	NA	21	NA	NA	NA
20	35R	—	—	+	—	<b>+/16, 26</b>	+	NA		NA	NA	NA
21	35C	—	—	—	—	<b>+/16</b>	—	NA		NA	NA	NA
22	121V	—	—	—	+	—	—	NA	29	NA	NA	NA
23	121R	—	—	—	—	—	+	NA		NA	NA	NA
24	121C	—	—	—	—	—	—	NA		NA	NA	NA
25	30V	—	+	—	—	—	—	NA	25	NA	NA	NA
26	30R	—	—	+	—	—	+	NA		NA	NA	NA
27	30C	—	—	—	—	—	—	NA		NA	NA	NA
28	319V	—	—	—	+	—	—	NA	34	NA	NA	NA
29	319R	—	—	+	—	—	+	NA		NA	NA	NA
30	319C	—	—	—	—	—	—	NA		NA	NA	NA

<sup>a</sup>NA, not available.<sup>b</sup>V, vagina; R, rectum; C, endocervix.<sup>c</sup>BV, bacterial vaginosis determined by Amsel criteria.<sup>d</sup>+ sign refers to the sample being positive (for the respective organism or disease listed at the top of the column), and the — sign refers to the sample being negative (for the respective organism or disease listed at the top of the column); bold italic +, detected by metagenomic shotgun sequencing (MSS).<sup>e</sup>Mean age, 28 years for cases and matched controls.<sup>f</sup>Load, *ompA* copy no./beta-actin copy no.; mean vaginal load, 1.72; mean endocervical load, 0.16; mean rectal load, 30.36; the letters G, Ja and F refer to the *ompA* genotype based on the sequence of the *ompA* gene, which is the gold standard for genotyping *C. trachomatis* strains.

**Endocervical, vaginal, and rectal microbiome alpha and beta diversity.** There were significant differences in alpha diversity across all three anatomic sites (Fig. 2A and B;  $P = 0.0005$ ; Kruskal-Wallis test). In pairwise comparisons, there was a significantly higher diversity in the rectum than in the vagina ( $P < 0.0005$ ) and the endocervix ( $P < 0.05$ ). Similarly, the diversity was higher in the endocervix than in the vagina for both *C. trachomatis*-positive (mean 3.8 versus 3.1) and *C. trachomatis*-negative (mean 2.7 versus 1.8) women, but this was not statistically significant. While there were no significant differences between *C. trachomatis*-negative and -positive microbiomes across all anatomic sites, there was a trend of an overall higher diversity for *C. trachomatis*-positive microbiomes (mean of 4.07 versus 3.26).


The relative abundance of the top 28 taxa (a limit set by One Codex) identified in the endocervix, vagina, and rectum is shown in Fig. 2A. Endocervical and vaginal microbial communities in *C. trachomatis*-negative women were dominated mostly by *L. iners* and *L. crispatus*, with an exception for 35C and 35V, which were dominated by *Alphapapillomavirus* 9 and 10. Sample 121 had no species at high (>25% of classified reads) or medium abundance (>5 to 25% of classified reads), with all organisms occurring at low abundance within 1 to 5%; there was insufficient abundance for representation in either site. *C. trachomatis*-



**FIG 1** Pipeline for clinical sample data generation, processing, and integration for the characterization of the endocervical, vaginal, and rectal microbiomes.

positive women had microbiomes comprised primarily of *G. vaginalis*, *Mageeibacillus indolicus*, *Prevotella* spp., and *Sneathia amnii* (Fig. 2A). The relative abundance in the vagina of *L. iners* and *L. crispatus* was significantly higher in *C. trachomatis*-negative than in *C. trachomatis*-positive women ( $P < 0.01$ ), whereas the relative abundance of *M. indolicus* ( $P < 0.01$ ), *Ruminococcus lactaris* ( $P < 0.05$ ), *Peptoniphilus lacrimalis* ( $P < 0.01$ ), *Anaerococcus tetradius* ( $P < 0.01$ ), and *Prevotella oris* ( $P < 0.05$ ) was significantly higher in *C. trachomatis*-positive than in *C. trachomatis*-negative women (Fig. 2C). In the endocervix, the relative abundance of *L. iners*, *L. crispatus*, and *L. jensenii* ( $P < 0.05$ ) was significantly higher in *C. trachomatis*-negative than in *C. trachomatis*-positive women, whereas the relative abundance of *M. indolicus* and *A. tetradius* ( $P < 0.05$ ) was significantly higher in *C. trachomatis*-positive than in *C. trachomatis*-negative women (Fig. 2D). The bacterial species in the endocervix and vagina mentioned above that were significantly higher in abundance in *C. trachomatis*-related pathogenic microbiota were all previously found to be in higher abundance in BV (39–44). All endocervical and vaginal microbial species for which the relative abundance was significantly altered between *C. trachomatis*-positive and -negative samples are shown in Fig. S2A and B.

The heatmap in Fig. 3A shows the top 25 species (species limit set by Nephele pipeline) in the Bray-Curtis hierarchical clustering of endocervical, vaginal, and rectal samples with three distinct clusters. The first cluster consisted of *C. trachomatis*-negative vaginal and endocervical samples with a predominance of *Prevotella amnii*, *G. vaginalis*, *A. vaginae*, *L. iners*, and *L. crispatus*. The second cluster consisted of a combination of *C. trachomatis*-positive and three *C. trachomatis*-negative vaginal and endocervical samples. *C. trachomatis*-negative samples 57V and 57C had 12 and 6 *C. trachomatis* reads, respectively, detected in their metagenomic sequencing data that were confirmed by BLASTn, which may represent prior infection. Sample 121C showed only *G. vaginalis*. The only rectal sample in this cluster




**FIG 2** Taxonomic composition of the endocervical, vaginal, and rectal microbiota. (A) The relative abundance bar plots represent the top 28 species within the microbial community structure of the *C. trachomatis*-positive and -negative women. The colored boxes below indicate the Shannon index. The grid below the Shannon index indicates the presence or absence of bacterial vaginosis (BV), human papillomavirus (HPV), *Neisseria gonorrhoeae* (Ng), *Candida albicans* (CA), and/or *Mycoplasma genitalium* (Mg). (B) Anatomic site-specific microbial Shannon diversity for the endocervix, vagina, and rectum. Rectal samples had a statistically significant difference in Shannon diversity compared with endocervical (\*,  $P < 0.05$ ) and vaginal (\*\*\*,  $P < 0.0005$ ) samples. The difference for endocervix versus vagina was not significant (ns) as measured by Kruskal-Wallis test and Dunn's multiple comparisons. The top 28 species in the vaginal (C) and endocervical (D) microbiomes with the most unique abundant gene content in VIRGO are plotted. Density curves for each species compare the distribution of the relative abundance of reads for the *C. trachomatis*-positive (in red) and -negative women (in green), and the vertical bars represent the individual data points. Significant differences in relative abundance of species between positive and negative women are shown (\*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ). Statistical significance was determined using two-sample Wilcoxon test between the *C. trachomatis*-positive and -negative samples. The x axis represents the  $\log_2$  of the ratio of the unique gene content of a species divided by the gene content of the entire community.

was 362R, which had a microbial composition similar to the microbiomes of 362C and 362V (see below). The other samples were dominated by BV pathogens, including *Clostridiales* genomsp., BVAB3, *P. amnii*, *G. vaginalis*, *A. vaginae*, *L. iners*, *Megasphaera* genomsp. type\_1, *Prevotella timonensis*, and *Megasphaera* spp. The third cluster consisted of rectal *C. trachomatis*-negative and -positive samples, a single *C. trachomatis*-negative cervical sample (30C), and *C. trachomatis*-positive samples 107C and 107V. The predominant species varied across rectal samples but consisted mainly of *Bifidobacterium adolescentis*, *Prevotella copri*, *Porphyromonas uenonis*, *Actinomyces turicensis*, *P. timonensis*, *Faecalibacterium prausnitzii*, *Eubacterium rectale*, and *Bacteroides fragilis* (Fig. 3A).

Principal-component analysis (PCoA) based on Bray-Curtis distance (beta diversity) showed clustering patterns (Fig. 3B) that were identical to hierarchical clustering shown in Fig. 3A, with rectal samples primarily clustering separately. Comparing the beta diversity between the *C. trachomatis*-negative and -positive samples in the vagina (Fig. 3C) and endocervix (Fig. 3D), each formed mostly separate clusters. No clear clusters were present for the rectal samples.

**Endocervical and vaginal microbiota structures and CSTs.** Vaginal and endocervical microbial species resolved into CST-III-A, CST-III-B, CST-IV-A, CST-IV-B, and CST-IV-C0



**FIG 3** Bray-Curtis hierarchical clustering of endocervical, vaginal, and rectal samples and principal coordinates analysis (PCoA) plot of samples from all three anatomic sites. (A) Clustering is based on species composition and percent abundance of microbial communities. Color key of percent abundance is indicated on the top: scale toward black (0) and yellow (100) indicates lower and higher percent abundance, respectively. Rows represent taxa, and columns represent samples. Grid below heatmap indicates the presence or absence of *C. trachomatis* (Ct), bacterial vaginosis (BV), human papillomavirus (HPV), *Neisseria gonorrhoeae* (Ng), *Candida* (CA), and *Mycoplasma genitalium* (Mg). (B) Principal coordinates analysis (PCoA) plot of samples from all three anatomic sites. *C. trachomatis*-positive and -negative samples from vaginal (C) and endocervical (D) sites based on Bray-Curtis distance (beta diversity). The first and second principal coordinates are represented.

(Table 2). CSTs were identified by the CST classifier VALENCIA that matches the microbiota profile to 13 reference centroids based on the similarity score (45). These scores were used to gauge confidence in the assignment and were helpful when there was no match or no close match to multiple centroids. In these cases, VALENCIA yielded a low confidence score (closer to zero), indicating ambiguity in the assigned CST (Table 2).

Comparing the relative abundance data for the four databases run through VALENCIA, VIRGO (18) had the highest overall similarity scores compared to One Codex, Kraken, and MetaPhlan, except for 30C, 35C, and 121C (Table 2). Although the score for 35C was the lowest for VIRGO, there was a relatively even community of *Prevotella* spp. with only 7% other spp., which was a better match with the reference CST-IV-C0 bacterial composition than CST-IV-C3, as determined by the other databases (Fig. S3). For 30C, both VIRGO and One Codex abundance data matched CST-IV-B, while 121C matched CST-IV-B for all databases; 121V was assigned CST-IV-B using the VIRGO database, although the microbiome was more similar to reference III-A (Fig. S4), which was the same for the other three databases. Similarly, 319C was assigned CST-IV-C0 but had a closer match to reference III-B (Fig. S5), as it did for the One Codex database.



**TABLE 2** Vaginal and endocervical community state types (CSTs)<sup>a</sup> using the CST classifier VALENCIA and the relative abundance data from One Codex, VIRGO, Kraken, and MetaPhlAn databases

Sample <sup>b</sup>	Status of:						VIRGO		One Codex		Kraken		MetaPhlAn	
	<i>C. trachomatis</i>	BV	<i>N. gonorrhoeae</i>	<i>Candida</i>	HPV	<i>M. genitalium</i>	CST <sup>c</sup>	Score	CST <sup>c</sup>	Score	CST <sup>c</sup>	Score	CST <sup>c</sup>	Score
72C	+	–	–	–	–	–	IV-B	<b>0.10</b>	IV-B	0.08	IV-B	0.006	IV-B	0.009
72V	+	+	–	–	–	–	IV-B	<b>0.14</b>	IV-B	0.06	IV-B	0.01	IV-B	0.01
98C	+	–	–	–	–	–	IV-B	<b>0.10</b>	IV-B	0.10	IV-B	0.007	IV-B	0.05
98V	+	+	–	–	–	–	IV-B	<b>0.73</b>	IV-B	0.10	IV-B	0.11	IV-B	0.05
107C	+	–	–	–	–	+	IV-A	<b>0.36</b>	IV-A	0.02	IV-B	0.01	IV-A	0.01
107V	+	+	–	–	–	+	IV-A	<b>0.15</b>	IV-A	0.01	IV-B	0.04	IV-A	0.01
192C	+	–	–	–	–	+	IV-B	<b>0.14</b>	IV-B	0.04	IV-B	0.01	IV-B	0.02
192V	+	–	–	–	+	+	IV-B	<b>0.50</b>	IV-B	0.04	IV-B	0.14	IV-B	0.04
362C	+	–	–	–	–	+	<u>IV-A</u>	<b>0.38</b>	IV-B	0.05	IV-B	0.18	IV-B	0.02
362V	+	–	–	–	–	+	<u>IV-A</u>	<b>0.36</b>	IV-B	0.04	IV-B	0.11	III-A	0.06
30C	–	–	–	–	–	–	IV-B	0.01	IV-B	0.03	III-A	0.001	III-A	<b>0.05</b>
30V	–	+	–	–	–	–	<u>IV-B</u>	<b>0.22</b>	III-B	0.13	III-B	0.20	III-A	0.12
35C	–	–	–	–	+	–	<b>IV-C0</b>	0.003	IV-C3	0.03	IV-C3	0.007	IV-C3	<b>0.09</b>
35V	–	+	–	+	+	–	<b>IV-B</b>	<b>0.18</b>	III-B	0.10	III-A	0.02	III-A	0.12
57C	–	–	–	–	–	+	IV-B	<b>0.35</b>	IV-B	0.14	IV-B	0.05	IV-B	0.05
57V	–	+	–	–	–	–	IV-B	<b>0.67</b>	IV-B	0.11	IV-B	0.12	IV-B	0.06
121C	–	–	–	–	–	–	<b>IV-B</b>	0.04	IV-B	<b>0.06</b>	IV-B	0.002	IV-B	0.05
121V	–	–	–	+	–	–	<b>IV-B (III-A)</b>	<b>0.68</b>	III-A	0.14	III-A	0.13	III-A	0.11
319C	–	–	–	–	–	–	<u>IV-C0</u> (III-B)	<b>0.20</b>	III-B	0.13	III-A	0.04	III-A	0.10
319V	–	–	–	+	–	–	III-B	<b>0.26</b>	III-B	0.17	III-A	0.07	III-A	0.11

<sup>a</sup>CSTs were assigned using the similarity of a microbiota profile to each of the 13 VALENCIA reference centroids based on the similarity score. VIRGO taxonomic data run in VALENCIA was used for defining CSTs;


<sup>b</sup>V, vagina; R, rectum; C, endocervix.

<sup>c</sup>Underlined CST, unique CST compared to the other three databases; bold italic CST, discordant between endocervix and vagina; CST in parentheses, assigned CST based on comparison with all VALENCIA reference centroids; bold score, highest value across all data sets; gray shading, variance from VIRGO CST; + sign refers to the sample being positive (for the respective organism or disease listed at the top of the column), and the – sign refers to the sample being positive (for the respective organism or disease listed at the top of the column); bold italic +, detected by metagenomic shotgun sequencing (MSS).

The microbiomes of *C. trachomatis*-negative women consisted of CST-III-A, CST-III-B, CST-IV-B, and CST-IV-C0, whereas *C. trachomatis*-positive women had CST-IV-A and CST-IV-B, although there was no significant association between *C. trachomatis* status and CST. *C. trachomatis*-negative patients 35 and 121 had discordant CSTs between the endocervix and vagina; 35V was assigned CST-IV-B with a best match to reference CST-IV-B (Fig. 4), whereas 35C was assigned, as described above, CST-IV-C0. 121V was assigned CST-III-A, while 121C was assigned CST-IV-B.

**Rectal enterotypes and existing gaps in the typing scheme.** The dominant genera of bacteria in the rectum, which probably reflects carryover from the gastrointestinal (GI) microbiome, have been defined by three enterotypes each dominated by *Bacteroides*, *Prevotella*, and *Ruminococcus*, respectively (46). These clusters may in fact be more appropriately characterized as a ratio of *Bacteroides* versus *Prevotella* abundance, with the *Ruminococcus* enterotype folded into the *Bacteroides* group (47, 48). Pathogenic rectal microbiota have been proposed to be characterized by reduced diversity with a shift away from commensal species. While the rectal microbiota is composed of primarily *Firmicutes*, *Bacteroidetes*, *Proteobacteria*, *Actinobacteria*, and *Fusobacteria*, our cohort occasionally also had microbiomes dominated by *Spirochaetes* and *Verrucomicrobia* (data not shown). Based on the enterotype method of classification (49), enterotype 2 (ET-P) was most common, which is dominated by genus *Prevotella*. Sample 98R was a combination of ET-P and enterotype 1 (ET-B), where *Bacteroides* predominates. However, four rectal microbiomes could not be placed into an enterotype and contained bacteria primarily from the genera *Gardnerella*, *Akkermansia*, *Bifidobacterium*, and *Brachyspira* (Fig. 5). There was no correlation between enterotype and *C. trachomatis* positivity, although the microbial composition of 362R was similar to the respective endocervical and vaginal microbiomes (Fig. 2).

**Predicted functional profiles of microbial communities in the endocervix, vagina, and rectum.** We characterized the microbial function at the whole-pathway level of the endocervical, vaginal, and rectal microbiomes using HUMAnN2 v3.0 (50).




**FIG 4** Pie chart representation of community state types (CSTs) for patient sample 35V identified by the CST classifier VALENCIA based on the taxonomic outputs generated by four different databases. Represented databases: VIRGO (A), One Codex (B), Kraken (D), and Metaphlan (E). The reference bacterial compositions for CST-III-B (C) and IV-B (F) are shown for comparison.

Substantial variability existed at the functional level across the three anatomic sites, with the samples segregating into three clusters based on pathway quantification (Fig. 6). The top 50 pathways (default pathway limit set by the Nephele pipeline) are visualized in the heatmap. Cluster 1 consisted of *C. trachomatis*-positive and -negative vaginal and cervical samples. Cluster 2 comprised only three endocervical samples. Cluster 3 consisted of rectal samples in addition to 107V, 362C, and 362V, where these three microbiomes were similar in composition to the rectal microbiomes. Samples 192V, 57V, and 98V in cluster 1 and samples 107V to 362V in cluster 3 had a higher abundance of pathways that were distinct from all other samples in cluster 1 and cluster 2.

No pathways were unique to the endocervical site. While the majority of the vaginal samples also had no unique pathways, the guanosine ribonucleotides *de novo* biosynthesis pathway of BVAB3 was unique to *C. trachomatis*-positive samples 72V, 107V, and 192V. Interestingly, 107V had many pathways driven by BV pathogens such as *Prevotella*, *BVAB3*, *Mobiluncus*, *Megasphaera*, *Peptoniphilus*, *Peptostreptococcus*, and *Anaerococcus* that were unique to this vaginal sample (Table S3). Several pathways that were identified as unique to the rectal site were also specific to rectal microbial species (Table S4). These pathways were mainly involved in chorismite, amino acid, coenzyme A (CoA), and nucleotide biosynthesis and carbohydrate metabolism. Sample 362R, which had a microbiome similar to vaginal microbiomes, had very few pathways unique to the rectum.

BV pathogens such as *P. amnii*, *P. timonensis*, *G. vaginalis*, *BVAB3*, *Peptostreptococcus anaerobius*, *P. uenonis*, and *Porphyromonas asaccharolytica* were the drivers of 57 pathways and showed a significant difference in abundance ( $P < 0.05$ ) between *C. trachomatis*-positive and -negative endocervical samples (Table S5). The predicted pathways characterizing *C. trachomatis*-positive endocervical samples were involved in the biosynthesis of peptidoglycan, CoA, dTDP-L-rhamnose, L-lysine, UMP, CDP-diacylglycerol, UDP-N-acetylmuramoyl-pentapeptide, guanosine ribonucleotides, and NAD. In the vagina, 11 pathways were significantly greater in abundance in *C. trachomatis*-positive than in *C. trachomatis*-negative samples and were




**FIG 5** Enterotypes of rectal microbiota based on taxonomic relative abundances at the genus level for *C. trachomatis*-positive and -negative women. Only genera with relative abundance of >1% on average are reported. Remaining taxa are grouped as “Other.” Enterotypes are indicated at the top of each relative abundance bar: enterotype 1 (ET-B), *Bacteroides* as the best indicator; enterotype 2, *Prevotella* as the driver, a genus whose abundance is inversely correlated with *Bacteroides* (ET-P); enterotype 3, distinguished by an overrepresentation of Firmicutes, most prominently *Ruminococcus* (ET-F, not present); N, indicates that an enterotype could not be predicted based on current enterotype compositions.

involved in CoA, amino acid, nucleotide and nucleoside, amines and polyamines, secondary metabolite, and enzyme factor biosynthesis (Table S6); 8 of the 11 pathways could not be attributed to microbiota at the species level. The remaining three pathways involved in CoA and nucleotide biosynthesis were driven by *P. amnii* and BVAB3.

A total of 38 pathways involved in carbohydrate, CoA, amino acid, cell structure, fatty acid and lipid, secondary metabolite, nucleotide and enzyme factor biosynthesis, and nucleoside, nucleotide, and carbohydrate degradation were significantly greater in abundance in the rectal *C. trachomatis*-positive samples than in the *C. trachomatis*-negative samples (Table S7). Nineteen of these pathways were found only in *P. lacrimalis*, *P. uenonis*, *F. prausnitzii*, *Collinsella aerofaciens*, *P. timonensis*, and *Eubacterium bifforme*.

Using VIRGO, we were able to characterize the abundance of genes within each species and categorize them into their functional categories for the vaginal and endocervical sites. While there was no significant difference in the average gene count across different functional categories between the vaginal *C. trachomatis*-positive and -negative samples, there was a clear difference in the species involved in the stratification of the functional categories (Fig. 7). Within the category of cellular processes and signaling, genes from the bacterial species *P. uenonis*, *P. anaerobius*, *P. lacrimalis*, *Peptoniphilus harei*, *Mobiluncus mulieris*, *Mobiluncus curtisii*, and *A. tetradius* were unique to *C. trachomatis*-positive compared to -negative samples. The pattern was very similar for the functional category information storage and processing and metabolism, where, in addition, *M. indolicus* was unique to *C. trachomatis*-positive compared to -negative samples. Similar to vaginal samples, there was no significant difference between the average gene count of functional categories between *C. trachomatis*-positive and -negative endocervical samples (Fig. S6). However, genes from *A. tetradius*, *Arcanobacter* spp., *C. trachomatis*,




**FIG 6** Spectral clustering of the top 50 predicted functional pathways in endocervical, vaginal, and rectal metagenomes. The clustering was based on the average abundance matrix of the predicted functional pathways with the greatest variance across the three anatomic sites. Rows represent the predicted functional categories of the bacterial communities, whereas the columns represent the sample identities. The color key of the average abundance is indicated above the heatmap. *C. trachomatis* infection status is indicated below the heatmap matrix. Key functional categories are indicated on the right above the functional pathway designations.

*Dialister microaerophilus*, *M. indolicus*, *M. curtisii*, *Mobiluncus mulieris*, *P. lacrimalis*, *P. anaerobius*, *Prevotella* spp., and *P. timonensis* were unique to *C. trachomatis*-positive samples for the functional category of cellular processes and signaling. In addition, *P. harei* was also unique to *C. trachomatis*-positive samples for the functional category of information storage and processing. *Peptostreptococcus* spp., *Escherichia coli*, *S. amnii*, *Sneathia sanguinegens*, and *R. lactaris* were unique to *C. trachomatis*-positive samples in addition to the species mentioned above for metabolism.

**DISCUSSION**

The last decade has provided a plethora of data on the vaginal microbiome, defining both healthy and pathogenic microbial profiles in addition to associations with various STIs. Far fewer studies have similarly examined the endocervix. To the best of our knowledge, this is the first study to investigate the microbial composition, structure,



**FIG 7** Functional profiling of the vaginal metagenomes for *C. trachomatis*-positive and -negative women. Functional categories were annotated using EggNOG v4.5 (see Materials and Methods). Functional profiles were stratified by species using the taxonomic profiling provided by VIRGO. y axis, functional categories; x axis, log 2 transformed gene counts for individual species.

and purported function of the endocervical, vaginal, and rectal microbiomes using MSS technology within and among women and also in association with *C. trachomatis* infection. Further, while several studies have highlighted racial and ethnic differences in the microbiome of healthy asymptomatic women as well as women with BV and STIs from ethnicities of European, Asian, African, and Hispanic descent (51–56), none have studied Pacific Islanders in these contexts.

The cohort of women in this study were of iTaukei ethnicity, which we had previously identified as at higher risk for STIs than Indo-Fijian and other Pacific Islanders (6). Women with *C. trachomatis* infection had a significantly higher mean load in the rectum than in the vagina and endocervix. It is possible that this reflects the higher percentage of human contamination for rectal than vaginal samples in that the former has not only a larger surface area of epithelial cells (approximate mean surface area of 193 to 212 cm<sup>2</sup>) (57) than the vagina (approximate mean surface area of 87 cm<sup>2</sup>) (58) but perhaps a greater number of cells that can be infected with *C. trachomatis* and then sloughed. This ties in with well-known trends in tissue-specific human contamination (59). However, one of our study subjects had a higher vaginal load that may

indicate intragenitoretal transmission given the similarity in composition across all three microbiomes. The latter case is consistent with a recent study in the Netherlands that found a higher mean vaginal load than concurrent anorectal infection (60). A much larger sample size will be needed to discern the clinical significance of differential loads among these anatomic sites.

The vaginal Xpert CT/NG and wet prep tests were able to detect *N. gonorrhoeae*, *Trichomonas vaginalis*, and *Candida* in the cervicovaginal environment, with one additional candidiasis case detected by MSS. MSS identified one other subject with rectal candidiasis for which there is no standard test. Interestingly, subject 57, who tested negative for *C. trachomatis*, had six *C. trachomatis* reads in the endocervix, 12 in the vagina, and 2 in the rectum, suggesting a prior infection that may have recently cleared but with the presence of residual DNA. Indeed, *C. trachomatis* DNA can be detected by commercial diagnostic tests for 2 to 4 weeks following successful treatment (61). MSS was also instrumental in detecting 2 subjects with HPV, 5 with rectal *N. gonorrhoeae*, and all 10 with *M. genitalium* infections (3 of whom had *M. genitalium* in other anatomic sites) where pap smear, rectal STI, and *M. genitalium* tests, respectively, were not available. The *N. gonorrhoeae* findings might be expected in that recent studies have found rectal infections in women to be as high as 13.4% irrespective of urogenital infections based on nucleic acid amplification tests (NAATs) (28, 62). However, finding *M. genitalium* in all rectal microbiomes was somewhat surprising, although rectal *M. genitalium* has frequently been reported as asymptomatic and more common than urogenital infections, at least among men who have sex with men (MSM) (63). There are extremely limited data on women, but our findings suggest that MSS may be more sensitive than NAATs in detecting rectal *M. genitalium*. MSS holds promise as a scalable global microbial “diagnostic” for STIs for near-future use.

The species-level alpha diversity among vaginal samples from our cohort was similar to that of other studies (64). However, we found that the diversity was higher in the endocervix than in the vagina for both *C. trachomatis*-positive (mean 3.8 versus 3.1) and -negative (mean 2.7 versus 1.8) women, although not statistically significantly. These results were supported by a study of high-risk adolescents in South Africa where the endocervix was also found to have a higher diversity than the vagina based on 16S rRNA sequencing (11).

While previous studies have largely asserted that endocervical and vaginal microbiomes have similar microbial populations (65, 66), this was not the case in our study. In general, for *C. trachomatis*-positive women, the relative abundance of *R. lactaris*, *P. lacrimalis*, *A. tetradius*, and *P. oris* was higher in the vagina than in the endocervix, whereas *A. tetradius* was higher in abundance in the endocervix. These data are consistent with a 16S rRNA sequencing-based study where young women were found to have significantly dissimilar microbiomes between the endocervix and vagina. For example, the abundant species in the former were *Achromobacter spanius*, *Gordonia terrae*, and *Enterococcus faecium* (11). Dissimilar microbiomes were also identified in a study of HPV infection among women in China (67). Another recent publication that did not address STIs also found differences in 16S rRNA microbial profiles between these two anatomic sites (68). Additional research is required to determine the full breadth of endocervical and vaginal microbial discordance among *C. trachomatis*-positive and -negative subjects and the statistical associations of microbial species with each.

The endocervical and vaginal microbiota were dominated by *L. iners* and *L. crispatus* in *C. trachomatis*-negative women. In the vagina, the relative abundance of *L. iners* and *L. crispatus* in *C. trachomatis*-negative women was significantly higher than that in *C. trachomatis*-positive women, whereas, in the endocervix, the relative abundance of *L. iners*, *L. crispatus*, and *L. jensenii* was significantly higher in *C. trachomatis*-negative than -positive women. *L. iners*-dominated sites also harbored strict anaerobes, such as *A. vaginae*, *G. vaginalis*, and *Prevotella* spp., defined as “Intermediate BV microbiota,” which is considered a transient state between the mixed anaerobic and *Lactobacillus*-

dominant microbiota (69). *L. iners* is biologically unique from other species of the genus since it is able to survive among different community members and also has a greater potential for disease pathogenesis (69–71). While these findings are somewhat surprising for *C. trachomatis*-negative women, they likely reflect the fact that many Fijian women have BV, similar to other minority, ethnic, and racial populations, such as Black and Hispanic women in the United States (44, 55, 56). Indeed, three of the five *C. trachomatis*-negative women in our study had clinical BV.

*C. trachomatis*-positive women had primarily polymicrobial vaginal and endocervical microbiomes comprised of *G. vaginalis*, *Prevotella* spp., *M. indolicus*, *Sneathia* spp., and *Veillonellaceae* spp., which are pathogens previously reported in several ethnicities with BV (72). In the vagina, the relative abundance of *M. indolicus*, *R. lactaris*, *P. lacrimalis*, *A. tetradius*, and *P. oris* in *C. trachomatis*-positive women was significantly higher than that in *C. trachomatis*-negative women, while, in the endocervix, the relative abundance of *M. indolicus* and *A. tetradius* was significantly higher than that in *C. trachomatis*-negative women. Although these species have previously been reported in association with BV, the combination among the *C. trachomatis*-positive women in this study appears to be unique to the Pacific Islanders.

Vaginal and endocervical samples were classified into CSTs using four databases and the VALENCIA classifier. The VIRGO database had the highest similarity scores compared to all other databases, which most likely reflects the fact that it was developed to include the current global diversity of vaginal microbial populations from North America, Africa, and Asia (18). However, there were five exceptions in our data set where VIRGO either had a lower score but the best CST match based on examination of the microbial composition or had the highest score but more closely matched another CST than the original assignment. Four of the five exceptions were endocervical samples (Table 2). These data suggest that the microbial populations of Pacific Islanders do not entirely fit the current VALENCIA classification system. Additional modifications to the CSTs will be required for endocervical and vaginal microbiomes of Pacific Islanders and other ethnic/racial groups as more globally diverse communities are examined in order to broaden our understanding of microbial profiles and structures across populations.

The rectal microbial profiles had an alpha diversity (mean of 5.2 for *C. trachomatis*-negative and 5.1 for *C. trachomatis*-positive women) much higher than those of the vagina and endocervix microbial profiles. Interestingly, *C. trachomatis*-positive subject 362 had a rectal microbial composition almost identical to the microbial profiles of the subject's endocervix and vagina as evidenced by clustering of 362R (Fig. 3B, yellow data point) with 362V and 362C (Fig. 3B, blue and pink data points) in the PCoA plot based on Bray-Curtis distance. There was similarity of composition across the anatomic sites, including *Veillonellaceae* spp., *S. amnii*, *Prevotella* spp., *M. genomosp. type\_1*, *M. indolicus*, *L. iners*, *G. vaginalis*, *Clostridioides difficile*, and *A. vaginae*. These data suggest a high degree of microbial sharing between anatomic sites or even transmission from the endocervix/vagina to the rectum. A recent study in Italy also found similarities between the vaginal and rectal taxa suggestive of microbial sharing along with what they described as dysbiosis in both sites (22). Overall, however, principal-component analysis showed that the microbial composition of the rectal samples clustered separately from the endocervical and vaginal samples with no distinct clustering based on *C. trachomatis* status.

The healthy human gastrointestinal (GI) microbiome has been found to be primarily composed of *Firmicutes*, *Bacteroidetes*, *Proteobacteria*, *Actinobacteria*, and *Fusobacteria* (46), which was consistent for the rectal microbiome of Pacific Islanders in our study. However, in our study, the rectal microbiome was occasionally also dominated by *Spirochaetes* and *Verrucomicrobia*. While a previous 16S rRNA study showed that *Firmicutes*, *Bacteroidetes*, *Proteobacteria*, and *Fusobacteria* were the top four dominant phyla in healthy and *C. trachomatis*-positive men who have sex with men (MSM) (35), our study showed that *Firmicutes*, *Bacteroidetes*, *Actinobacteria*, and *Fusobacteria* were the top four in *C. trachomatis*-negative

women and *Firmicutes*, *Bacteroidetes*, *Actinobacteria*, and *Proteobacteria* were the top four in *C. trachomatis*-positive women. Six of 10 women (2/6 *C. trachomatis*-negative and 4/6 *C. trachomatis*-positive) in our study also had a higher *Prevotella/Bacteroides* ratio, characteristic of a high-fiber and -carbohydrate diet of nonwesternized populations, which was similar to previous 16S and reverse transcription quantitative PCR (RT-qPCR) studies on the fecal microbiota of adults in Papua New Guinea (73, 74).

Due to a lack of convention for classifying rectal microbiota, we used the enterotype classification system, which is based on GI microbiota (49, 75), as a proxy. We also used three of the largest available metagenomic data sets, including the Human Microbiome Project (HMP), MetaHIT, and a Chinese type II diabetes study. We found that Pacific Islanders primarily had ET-P dominated by the genus *Prevotella* but also ET-B dominated by *Bacteroides* and one subject with a mixed ET-B/P enterotype. However, the microbial profile of two *C. trachomatis*-positive and two *C. trachomatis*-negative women was unique. These rectal microbiomes were dominated by *Gardnerella* and *Brachyspira* for *C. trachomatis*-positive women and *Akkermansia*, *Bifidobacterium*, and *Blautia* for *C. trachomatis*-negative women. The data highlight the limitations to the enterotype classification system because it does not entirely represent the rectal microbiome, and the resulting stratification only partially reflects the more complex structure in our population. Consequently, there is a need for improved modeling and inclusion of globally diverse communities to create typing schemes that are more inclusive. This would allow for a systematic comparison of Pacific Islander microbiomes to those of westernized or other ethnic populations that currently is not possible.

A higher involvement of CoA, aromatic amino acids, nucleotide and nucleoside, and enzyme factor biosynthesis pathways was predicted in the microbiome of *C. trachomatis*-positive patients, and many of these pathways were driven by pathogens associated with BV. Although functional studies to understand the dynamics of these anatomic ecological niches are warranted, we can speculate that these changes in metabolic activities are associated with pathogenic microbes and that the presence of these pathways in other bacteria result in support of chlamydial intracellular survival, growth, and development (76). For instance, *C. trachomatis* is dependent on the aromatic amino acid tryptophan. Most, but not all, genital and rectal *C. trachomatis* strains are tryptophan auxotrophs with tryptophan biosynthesis capabilities using substrates such as indole (77, 78). However, the organism can also scavenge tryptophan produced by other bacteria in the microbiome (79). Fundamentally, *C. trachomatis* displays reduced metabolic capabilities compared to its free-living *Chlamydia*-like counterparts and is therefore dependent on a wide range of host-derived metabolic precursors, purines and pyrimidines, and various cofactors (76). In support of our data, a recent 16S rRNA sequencing-based study of the vaginal microbiome predicted higher chorismate, a precursor of indole, and biosynthesis of aromatic amino acids in *C. trachomatis*-positive subjects than in *C. trachomatis*-negative subjects (22).

We found a higher abundance of CoA biosynthesis that was driven primarily by anaerobic BV pathogens in the *C. trachomatis*-infected endocervical, vaginal, and rectal microbiomes. CoA plays an important role in the citric acid cycle to generate energy and in mixed acid fermentation. Indeed, fermentation produces short-chain fatty acids that are one of the main drivers of an imbalance in the microbiota that can lead to disease pathogenesis (80). While a previous study also reported similar trends of increased fermentation in the *C. trachomatis*-positive vaginal microbiome (22), it was not clear if the pathways identified were driven by BV-associated pathogens.

The predicted pathways involving peptidoglycan biosynthesis and pyrimidine and purine metabolism by BV pathogens such as *G. vaginalis* were in higher abundance in the *C. trachomatis*-infected endocervical and rectal microbiomes than in the vaginal microbiome. Importantly, the *C. trachomatis*-infected endocervix had a number of metabolic pathways for CoA, amino acid, nucleoside and nucleotide, and enzyme biosynthesis driven by pathogens such as *Clostridiales*, *P. uenonis*, *P. amnii*, *P. timonensis*, and *Pophyromonas asaccharolytica* that were 5-fold higher than in the vagina. A recent



study reported similar findings of a relatively more active and complex metabolism occurring in the HPV-infected endocervix compared to the vagina (67). Furthermore, folate, carbohydrate, cell structure, fatty acid and lipid, and secondary metabolite biosynthesis and amino acid and carbohydrate degradation pathways driven by *G. vaginalis*, *P. lacrimalis*, *P. uenonis*, and *Peptostreptococcus* were unique to the *C. trachomatis*-infected endocervix compared to the vagina. These functions are likely important for the survival of the aforementioned pathogens but also may indirectly support *C. trachomatis* infection. These novel data suggest that microbial functions in the endocervix are more diverse and complex than those in the vagina during *C. trachomatis* infection.

We acknowledge the limitation of our small sample size comparing the *C. trachomatis*-positive and -negative groups across the anatomic sites. The findings nevertheless provide a detailed pipeline and, more importantly, greater insight into the microbiomes of Pacific Islanders. Further research, including larger prospective studies, is required to unravel the role of microbiomes in acquisition and prevention of *C. trachomatis* infection and to better classify the genitorectal microbiomes in this population.

## MATERIALS AND METHODS

**Study design and sample characteristics.** Women attending the Fijian Ministry of Health and Medical Services (MoHMS) health centers and outreach clinics in the Central Division, Viti Levu, Fiji were consequently enrolled in a nonprobability parent study after informed consent as described previously (6). Women were excluded from the study if they were HIV positive, had untreated syphilis, had a diagnosis of cancer, or had been treated with antibiotics within the prior month.

Endocervical, vaginal, and rectal swab samples were collected similarly by trained clinicians and placed in SWAB/A-50 buffer (Cepheid, Sunnyvale, CA) and 1 mL of M4 medium (Remel, Lenexa, KS). Vaginal samples were collected as described previously (6). To ensure no contamination of the endocervix with vaginal material, after inserting the speculum and visualizing the cervix, the ectocervix was cleaned with a large swab to remove any material at this site, including the cervical os. A FLOQ swab (Copan) was then carefully inserted through the os into the endocervix without touching the speculum or walls of the vagina. Rectal samples were collected last using a FLOQ swab. All samples were stored at 4°C for no more than 4 h before transport to the lab at the same temperature. Vaginal samples in Cepheid buffer were kept at 4°C until processed same day; remnant Cepheid buffer samples were stored at -80°C. All samples for MSS were immediately placed at -80°C until processed.

Vaginal samples were tested for *C. trachomatis* and *N. gonorrhoeae* using the nucleic acid amplification test (NAAT) Xpert CT/NG test (Cepheid). Endocervical, vaginal, and rectal samples were tested by an in-house qPCR to detect the *C. trachomatis* single-copy *ompA* gene and human single-copy beta-actin gene and to quantitate each as we described previously (37). *C. trachomatis* genome copy number was then divided by the beta-actin genome copy number to arrive at the number of *C. trachomatis* genomes per cell.

All swab samples (stored at -80°C) along with clinical data and test results for *C. trachomatis*, beta-actin, *Trichomonas vaginalis*, *Candida*, and BV were provided by the parent study deidentified using a unique ID number with no trace to patient identifiers. We randomly selected (using a table of random numbers) five women with confirmed *C. trachomatis* infection in all three anatomic sites and age-matched them to five women without *C. trachomatis* infection in any site (Table 1).

**Nucleic acid extraction, library construction, and MSS.** Genomic DNA (gDNA) was extracted from endocervical, vaginal, and rectal swab samples from the 10 women (Fig. 1). Briefly, cells were lysed using 100  $\mu$ L of lysozyme (10 mg/mL; Sigma-Aldrich), 12  $\mu$ L of mutanolysin (25,000 U/mL; Sigma-Aldrich), and 6  $\mu$ L of lysostaphin (4,000 U/mL in sodium acetate; Sigma-Aldrich) and incubated for 1 h at 37°C as we described previously (37). DNA was isolated from the resulting crude lysate using the QIAamp DNA minikit (Qiagen) as per the manufacturer's instructions with elution in 100  $\mu$ L of AE buffer. DNA concentration was measured using the Qubit double-stranded DNA (dsDNA) broad-range (BR) assay kit (Invitrogen). MSS libraries were constructed using Illumina Nextera XT kits and sequenced using 150-nucleotide paired-end reads on an Illumina HiSeq 2500 platform.

**Identification of endocervical, vaginal, and rectal microbiota and metabolic function.** Raw MSS sequence data were processed using FastQC v1.0.0 (81) to identify any problem areas in the data. TrimGalore v0.6.5 (82) was used to excise Illumina adapters, trim reads at an average quality score threshold of Q15, and remove reads containing ambiguous bases or sequences that were too short. All human reads were removed using Kneaddata v. 0.11.0 (83) (Fig. 1). Bacterial and viral reads were confirmed by BLASTn (query coverage of >95% and sequence identity of >95%) to the species level using custom python scripts back in blast.sh and BLAST\_to\_Excel.py (<https://github.com/ddeanlab/Fiji-10-Patients-MSS>). The number of confirmed reads for a pathogen was divided by the total number of reads for a sample, excluding human reads, and then multiplied by 1 million to arrive at a value for reads per million (RPM) for that pathogen as described by Babiker et al. (38).

The NIH-supported Nephel metagenome pipeline (84) was used on the raw reads, including the bioBakery package MetaPhlan v3.0 (84) for species identification, StrainPhlan v3.0 (50) for identifying single nucleotide polymorphism (SNP) variation within species, and HUMAnN2 v3.0 (50) for identifying

functional modules (Fig. 1). Functional pathways unique to each anatomic site were identified using a custom python script `path_abundance.py`.

One Codex (85), Kraken v2.0 (86), MetaPhlan 3.0 (84), and VIRGO (18) were used to determine the taxonomic composition and presence of bacteria, fungi, protozoa, and viruses in each sample.

**Determination of CSTs for endocervical and vaginal samples.** For classification of vaginal and endocervical microbiota into CSTs, a nearest-centroid-based algorithm, VALENCIA (45), was applied to taxonomic files generated independently by One Codex, Kraken v2.0, MetaPhlan v3.0, and VIRGO. CSTs were assigned based on the similarity of a microbiota profile to each of the 15 reference centroids calculated using Yue and Clayton's  $\theta$  (87). This yielded an array of 15 similarity scores, ranging from 0.0 (no shared taxa) to 1.0 (all taxa shared at the same relative abundance) for each sample. The reference centroid to which the sample bears the highest similarity score provided an assignment to a sub-CST.

**Enterotyping of rectal microbiota.** Phylum- and genus-level relative abundance of rectal samples was calculated and plotted in One Codex. Rectal samples were classified based on three enterotypes by the following criteria (49): (i) enterotype 1 (ET-B), with *Bacteroides* as its best indicator, (ii) enterotype 2 (ET-P), driven by *Prevotella*, a genus whose abundance is inversely correlated with *Bacteroides*, and (iii) enterotype 3 (ET-F), distinguished by an overrepresentation of *Firmicutes*, most prominently *Ruminococcus* (49).

**Statistical analysis and visualization.** Relative abundance of the top 28 species predicted by One Codex in the combined *C. trachomatis*-positive and *C. trachomatis*-negative samples for each site was compared using the one-sample Wilcoxon test and visualized using R software (88) and the ggplot2 package (v3.3.3) (89). The Shannon and Simpson index alpha-diversity was calculated in One Codex, and the Wilcoxon rank sum test was used to compare *C. trachomatis*-positive and -negative samples for each anatomic site. To visualize distances between samples, we used PCoA plots based on taxa at species rank and PCoA plots based on the beta-diversity metric Bray-Curtis dissimilarity, Manhattan distance, Jaccard distance, weighted UniFrac, and unweighted UniFrac. Bray-Curtis dissimilarity plot was chosen and plotted for samples from all three sites in One Codex. Heatmaps of the average species abundance (Spearman and Bray-Curtis) were plotted in Nephel. Wilcoxon rank sum test was used on pathway abundance files generated from HUMAnN2 v3.0 to compare *C. trachomatis*-positive and -negative samples for each anatomical site using the custom script `Pathway_statistics.RMD`. The average abundances of the top 50 functional pathways were plotted using Nephel.

**Data availability.** The human read-removed FASTQ files were submitted to the SRA under the BioProject accession number [PRJNA826539](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA826539).

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**SUPPLEMENTAL FILE 1**, PDF file, 4.2 MB.

## ACKNOWLEDGMENTS

We thank the parent study for providing the deidentified data for this study and Fijian colleagues: Rachel Devi, Kinisimere Nadredre, Mere Kurulo, and Darshika Balak. This research was supported by a Public Health Service grant from the National Institutes of Health R01 AI151075 (to D.D. and T.D.R.).

## REFERENCES

1. WHO. 2018. Report on global sexually transmitted infection surveillance. World Health Organization, Geneva, Switzerland.
2. CDC. 2019. Sexually transmitted disease surveillance. Centers for Disease Control and Prevention, Atlanta, GA.
3. WHO Regional Office for the Western Pacific. 2012. WHO multi-country cooperation strategy for the Pacific 2013–2017. WHO Regional Office for the Western Pacific, Manila, Philippines.
4. Cliffe SJ, Tabrizi S, Sullivan EA, Pacific Islands Second Generation HIV Surveillance Group. 2008. Chlamydia in the Pacific region, the silent epidemic. *Sex Transm Dis* 35:801–806. <https://doi.org/10.1097/OLQ.0b013e318175d885>.
5. Sullivan EA, Koro S, Tabrizi S, Kaldor J, Poumerol G, Chen S, O'Leary M, Garland SM. 2004. Prevalence of sexually transmitted diseases and human immunodeficiency virus among women attending prenatal services in Apia, Samoa. *Int J STD AIDS* 15:116–119. <https://doi.org/10.1258/095646204322764316>.
6. Svigals V, Blair A, Muller S, Sahu Khan A, Faktaufon D, Kama M, Tamani T, Esfandiari L, O'Brien M, Dean D. 2020. Hyperendemic *Chlamydia trachomatis* sexually transmitted infections among females represent a high burden of asymptomatic disease and health disparity among Pacific Islanders in Fiji. *PLoS Negl Trop Dis* 14:e0008022. <https://doi.org/10.1371/journal.pntd.0008022>.
7. WHO. 2005. Sexually transmitted and other reproductive tract infections—a guide to essential practice-2005. World Health Organization, Geneva, Switzerland.
8. Darville T, Hiltke TJ. 2010. Pathogenesis of genital tract disease due to *Chlamydia trachomatis*. *J Infect Dis* 201 Suppl 2:S114–S125. <https://doi.org/10.1086/652397>.
9. Hafner LM. 2015. Pathogenesis of fallopian tube damage caused by *Chlamydia trachomatis* infections. *Contraception* 92:108–115. <https://doi.org/10.1016/j.contraception.2015.01.004>.
10. van der Veer C, Bruisten SM, van der Helm JJ, de Vries HJC, van Houdt R. 2017. The cervicovaginal microbiota in women notified for *Chlamydia trachomatis* infection: a case-control study at the sexually transmitted infection outpatient clinic in Amsterdam, The Netherlands. *Clin Infect Dis* 64:24–31. <https://doi.org/10.1093/cid/ciw586>.
11. Balle C, Lennard K, Dabee S, Barnabas SL, Jaumdally SZ, Gasper MA, Maseko V, Mbulawa ZZA, Williamson A-L, Bekker L-G, Lewis DA, Passmore J-AS, Jaspán HB. 2018. Endocervical and vaginal microbiota in South African adolescents with asymptomatic *Chlamydia trachomatis* infection. *Sci Rep* 8:11109. <https://doi.org/10.1038/s41598-018-29320-x>.
12. Ziklo N, Vidgen ME, Taing K, Huston WM, Timms P. 2018. Dysbiosis of the vaginal microbiota and higher vaginal kynurenine/tryptophan ratio reveals an association with *Chlamydia trachomatis* genital infections. *Front Cell Infect Microbiol* 8:1. <https://doi.org/10.3389/fcimb.2018.00001>.
13. Brotman RM. 2011. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. *J Clin Invest* 121:4610–4617. <https://doi.org/10.1172/JCI57172>.

14. Tamarelle J, Ma B, Gajer P, Humphrys MS, Terplan M, Mark KS, Thiébaud ACM, Forney LJ, Brotman RM, Delarocque-Astagneau E, Bavoil PM, Ravel J. 2020. Nonoptimal vaginal microbiota after azithromycin treatment for *Chlamydia trachomatis* infection. *J Infect Dis* 221:627–635. <https://doi.org/10.1093/infdis/jiz499>.
15. Gupta VK, Paul S, Dutta C. 2017. Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. *Front Microbiol* 8:1162. <https://doi.org/10.3389/fmicb.2017.01162>.
16. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ. 2011. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A* 108 Suppl 1:4680–4687. <https://doi.org/10.1073/pnas.1002611107>.
17. Low N, Chersich MF, Schmidlin K, Egger M, Francis SC, van de Wijert HHM, Hayes RJ, Baeten JM, Brown J, Delany-Moretlwe S, Kaul R, McGrath N, Morrison C, Myer L, Temmerman M, van der Straten A, Watson-Jones D, Zwaren M, Martin Hilber A. 2011. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. *PLoS Med* 8:e1000416. <https://doi.org/10.1371/journal.pmed.1000416>.
18. Ma B, France MT, Crabtree J, Brotman RM, Ravel J, Holm JB, Humphrys MS. 2020. A comprehensive non-redundant gene catalog reveals extensive within-community intraspecies diversity in the human vagina. *Nat Commun* 11:940. <https://doi.org/10.1038/s41467-020-14677-3>.
19. Goltsman DSA, Sun CL, Proctor DM, DiGiulio DB, Robaczewska A, Thomas BC, Shaw GM, Stevenson DK, Holmes SP, Banfield JF, Relman DA. 2018. Metagenomic analysis with strain-level resolution reveals fine-scale variation in the human pregnancy microbiome. *Genome Res* 28:1467–1480. <https://doi.org/10.1101/gr.236000.118>.
20. Serrano MG, Parikh H, Brooks JP, Edwards DJ, Arodz TJ, Edupuganti L, Huang B, Girerd PH, Bokhari YA, Bradley SP, Brooks JL, Dickinson MR, Drake JJ, Duckworth RA, 3rd, Fong SS, Glascock AL, Jean S, Jimenez NR, Khoury J, Koparde VN, Lara AM, Lee V, Matveyev AV, Milton SH, Mistry SD, Rozycki SK, Sheth NU, Smirnova E, Vivadelli SC, Wijesooriya NR, Xu J, Xu P, Chaffin DO, Sexton AL, Gravett MG, Rubens CE, Hendricks-Muñoz KD, Jefferson KK, Strauss JF, 3rd, Fettweis JM, Buck GA. 2019. Racioethnic diversity in the dynamics of the vaginal microbiome during pregnancy. *Nat Med* 25:1001–1011. <https://doi.org/10.1038/s41591-019-0465-8>.
21. Filardo S, Di Pietro M, Tranquilli G, Latino MA, Recine N, Porpora MG, Sessa R. 2019. Selected immunological mediators and cervical microbial signatures in women with *Chlamydia trachomatis* infection. *mSystems* 4:e000094-19. <https://doi.org/10.1128/mSystems.00094-19>.
22. Raimondi S, Candelieri F, Amaretti A, Foschi C, Morselli S, Gaspari V, Rossi M, Marangoni A. 2021. Vaginal and anal microbiome during *Chlamydia trachomatis* infections. *Pathogens* 10:1347. <https://doi.org/10.3390/pathogens10101347>.
23. Raimondi S, Candelieri F, Amaretti A, Foschi C, Morselli S, Gaspari V, Rossi M, Marangoni A, Filardo S, Di Pietro M, Tranquilli G, Latino MA, Recine N, Porpora MG, Sessa R, Tamarelle J, de Barbeyrac B, Le Hen I, Thiébaud A, Bébér C, Ravel J, Delarocque-Astagneau E. 2021. Vaginal microbiota composition and association with prevalent *Chlamydia trachomatis* infection: a cross-sectional study of young women attending a STI clinic in France. *mSystems* 94:616–618. <https://doi.org/10.1136/sextans-2017-053346>.
24. Filardo S, Di Pietro M, Porpora MG, Recine N, Farcomeni A, Latino MA, Sessa R. 2017. Diversity of cervical microbiota in asymptomatic *Chlamydia trachomatis* genital infection: a pilot study. *Front Cell Infect Microbiol* 7:321. <https://doi.org/10.3389/fcimb.2017.00321>.
25. van Liere GAFS, van Rooijen MS, Hoebe CJP, Heijman T, de Vries HJC, Dukers-Muijers NHTM. 2015. Prevalence of and factors associated with rectal-only *Chlamydia* and *Gonorrhoea* in women and in men who have sex with men. *PLoS One* 10:e0140297. <https://doi.org/10.1371/journal.pone.0140297>.
26. Yeruva L, Spencer N, Bowlin AK, Wang Y, Rank RG. 2013. Chlamydial infection of the gastrointestinal tract: a reservoir for persistent infection. *Pathog Dis* 68:88–95. <https://doi.org/10.1111/2049-632X.12052>.
27. Qin X, Zheng H, Xue Y, Ren X, Yang B, Huang J, Huang S, Wu X, Zeng W, Ou J, Lan Y, Tang S. 2016. Prevalence of *Chlamydia trachomatis* genotypes in men who have sex with men and men who have sex with women using multilocus VNTR analysis-ompA typing in Guangzhou. *PLoS One* 11:e0159658. <https://doi.org/10.1371/journal.pone.0159658>.
28. Hunte T, Alcaide M, Castro J. 2010. Rectal infections with *Chlamydia* and *Gonorrhoea* in women attending a multiethnic sexually transmitted diseases urban clinic. *Int J STD Aids* 21:819–822. <https://doi.org/10.1258/ijsa.2010.009279>.
29. Kong FYS, Hocking JS. 2015. Treatment challenges for urogenital and anorectal *Chlamydia trachomatis*. *BMC Infect Dis* 15:293. <https://doi.org/10.1186/s12879-015-1030-9>.
30. Kong FYS, Tabrizi SN, Law M, Vodstrcil LA, Chen M, Fairley CK, Guy R, Bradshaw C, Hocking JS. 2014. Azithromycin versus doxycycline for the treatment of genital *Chlamydia* infection: a meta-analysis of randomized controlled trials. *Clin Infect Dis* 59:193–205. <https://doi.org/10.1093/cid/ciu220>.
31. McHardy IH, Li X, Tong M, Ruegger P, Jacobs J, Borneman J, Anton P, Braun J. 2013. HIV infection is associated with compositional and functional shifts in the rectal mucosal microbiota. *Microbiome* 1:26. <https://doi.org/10.1186/2049-2618-1-26>.
32. Vujkovic-Cvijin I, Somsouk M. 2019. HIV and the gut microbiota: composition, consequences, and avenues for amelioration. *Curr HIV/AIDS Rep* 16:204–213. <https://doi.org/10.1007/s11904-019-00441-w>.
33. Gonzalez SM, Aguilar-Jimenez W, Su R-C, Rugeles MT. 2019. Mucosa: key interactions determining sexual transmission of the HIV Infection. *Front Immunol* 10:144. <https://doi.org/10.3389/fimmu.2019.00144>.
34. Liu J, Williams B, Frank D, Dillon SM, Wilson CC, Landay AL. 2017. Inside out: HIV, the gut microbiome, and the mucosal immune system. *J Immunol* 198:605–614. <https://doi.org/10.4049/jimmunol.1601355>.
35. Ceccarani C, Marangoni A, Severgnini M, Camboni T, Laghi L, Gaspari V, D'Antuono A, Foschi C, Re MC, Consolandi C. 2019. Rectal microbiota associated with *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections in men having sex with other men. *Front Cell Infect Microbiol* 9:358. <https://doi.org/10.3389/fcimb.2019.00358>.
36. Amabebe E, Anumba DOC. 2020. Female gut and genital tract microbiota-induced crosstalk and differential effects of short-chain fatty acids on immune sequelae. *Front Immunol* 11:2184. <https://doi.org/10.3389/fimmu.2020.02184>.
37. Bowden KE, Joseph SJ, Cartee JC, Ziklo N, Danavall D, Raphael BH, Read TD, Dean D. 2021. Whole-genome enrichment and sequencing of *Chlamydia trachomatis* directly from patient clinical vaginal and rectal swabs. *mSphere* 6:e01302-20. <https://doi.org/10.1128/mSphere.01302-20>.
38. Babiker A, Bradley HL, Stittleburg VD, Ingersoll JM, Key A, Kraft CS, Waggoner JJ, Piantadosi A. 2021. Metagenomic sequencing to detect respiratory viruses in persons under investigation for COVID-19. *J Clin Microbiol* 59:e02142-20. <https://doi.org/10.1128/JCM.02142-20>.
39. Srinivasan S, Hoffman NG, Morgan MT, Matsen FA, Fiedler TL, Hall RW, Ross FJ, McCoy CO, Bumgarner R, Marrazzo JM, Fredricks DN. 2012. Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. *PLoS One* 7:e37818. <https://doi.org/10.1371/journal.pone.0037818>.
40. Nelson TM, Borgogna J-LC, Brotman RM, Ravel J, Walk ST, Yeoman CJ. 2015. Vaginal bioactive amines: biomarkers of bacterial vaginosis or precursors to vaginal dysbiosis? *Front Physiol* 6:253.
41. Pramanick R, Mayadeo N, Warke H, Begum S, Aich P, Aranha C. 2019. Vaginal microbiota of asymptomatic bacterial vaginosis and vulvovaginal candidiasis: are they different from normal microbiota? *Microb Pathog* 134:103599. <https://doi.org/10.1016/j.micpath.2019.103599>.
42. Onderdonk AB, Delaney ML, Fichorova RN. 2016. The human microbiome during bacterial vaginosis. *Clin Microbiol Rev* 29:223–238. <https://doi.org/10.1128/CMR.00075-15>.
43. Muzny CA, Taylor CM, Swords WE, Tamhane A, Chattopadhyay D, Cerca N, Schwebke JR, Martínez-Peña MD, Castro-Escarpullí G, Aguilera-Arreola MG. 2019. An updated conceptual model on the pathogenesis of bacterial vaginosis. *BMC Infect Dis* 13:189.
44. Muzny CA, Schwebke JR. 2016. Pathogenesis of bacterial vaginosis: discussion of current hypotheses. *J Infect Dis* 214:S1–S5. <https://doi.org/10.1093/infdis/jiw121>.
45. France MT, Ma B, Gajer P, Brown S, Humphrys MS, Holm JB, Waetjen LE, Brotman RM, Ravel J. 2020. VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. *Microbiome* 8:166. <https://doi.org/10.1186/s40168-020-00934-6>.
46. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto J-M, Bertalan M, Borrrel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Doré J, Antolin M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariac G, Dervyn R, MetaHIT Consortium, et al. 2011. Enterotypes of the human gut microbiome. *Nature* 473:174–180. <https://doi.org/10.1038/nature09944>.

47. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y-Y, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. 2011. Linking long-term dietary patterns with gut microbial enterotypes. *Science* 334:105–108. <https://doi.org/10.1126/science.1208344>.
48. Clemente JC, Ursell LK, Parfrey LW, Knight R. 2012. The impact of the gut microbiota on human health: an integrative view. *Cell* 148:1258–1270. <https://doi.org/10.1016/j.cell.2012.01.035>.
49. Costea PI, Hildebrand F, Arumugam M, Bäckhed F, Blaser MJ, Bushman FD, de Vos WM, Ehrlich SD, Fraser CM, Hattori M, Huttenhower C, Jeffery IB, Knights D, Lewis JD, Ley RE, Ochman H, O'Toole PW, Quince C, Relman DA, Shanahan F, Sunagawa S, Wang J, Weinstock GM, Wu GD, Zeller G, Zhao L, Raes J, Knight R, Bork P. 2018. Enterotypes in the landscape of gut microbial community composition. *Nat Microbiol* 3:8–16. <https://doi.org/10.1038/s41564-017-0072-8>.
50. Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, Mailyan A, Manghi P, Scholz M, Thomas AM, Valles-Colomer M, Weingart G, Zhang Y, Zolfo M, Huttenhower C, Franzosa EA, Segata N. 2021. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. *Elife* 10:e65088. <https://doi.org/10.7554/eLife.65088>.
51. Huang B, Fettweis JM, Brooks JP, Jefferson KK, Buck GA. 2014. The changing landscape of the vaginal microbiome. *Clin Lab Med* 34:747–761. <https://doi.org/10.1016/j.cll.2014.08.006>.
52. Ness RB, Hillier S, Richter HE, Soper DE, Stamm C, Bass DC, Sweet RL, Rice P. 2003. Can known risk factors explain racial differences in the occurrence of bacterial vaginosis? *J Natl Med Assoc* 95:201–212.
53. Zhou X, Brown CJ, Abdo Z, Davis CC, Hansmann MA, Joyce P, Foster JA, Forney LJ. 2007. Differences in the composition of vaginal microbial communities found in healthy Caucasian and black women. *ISME J* 1:121–133. <https://doi.org/10.1038/ismej.2007.12>.
54. Zhou X, Bent SJ, Schneider MG, Davis CC, Islam MR, Forney LJ. 2004. Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. *Microbiology (Reading)* 150: 2565–2573. <https://doi.org/10.1099/mic.0.26905-0>.
55. Alcendor DJ. 2016. Evaluation of health disparity in bacterial vaginosis and the implications for HIV-1 acquisition in African American Women. *Am J Reprod Immunol* 76:99–107. <https://doi.org/10.1111/aji.12497>.
56. Borgdorff H, van der Veer C, van Houdt R, Alberts CJ, de Vries HJ, Bruisten SM, Snijder MB, Prins M, Geerlings SE, Schim van der Loeff MF, van de Wijkert JHMM. 2017. The association between ethnicity and vaginal microbiota composition in Amsterdam, the Netherlands. *PLoS One* 12:e0181135. <https://doi.org/10.1371/journal.pone.0181135>.
57. Sadahiro S, Ohmura T, Yamada Y, Saito T, Taki Y. 1992. Analysis of length and surface area of each segment of the large intestine according to age, sex and physique. *Surg Radiol Anat* 14:251–257. <https://doi.org/10.1007/BF01794949>.
58. Pendergrass PB, Belovicz MW, Reeves CA. 2003. Surface area of the human vagina as measured from vinyl polysiloxane casts. *Gynecol Obstet Invest* 55:110–113. <https://doi.org/10.1159/000070184>.
59. Methé BA, Nelson KE, Pop M, Creasy HH, Giglio MG, Huttenhower C, Gevers D, Petrosino JF, Abubucker S, Badger JH, Chinwalla AT, Earl AM, FitzGerald MG, Fulton RS, Hallsworth-Pepin K, Lobos EA, Madupu R, Magrini V, Martin JC, Mitreva M, Muzny DM, Sodergren EJ, Versalovic J, Wollam AM, Worley KC, Wortman JR, Young SK, Zeng Q, Aagaard KM, Abolude OO, Allen-Vercoe E, Alm EJ, Alvarado L, Andersen GL, Anderson S, Appelbaum E, Arachchi HM, Armitage G, Arze CA, Ayvaz T, Baker CC, Begg L, Belachew T, Bhonagiri V, Bihan M, Blaser MJ, Bloom T, Bonazzi VR, Brooks P, Buck GA, Buhay CJ, Busam DA, Campbell JL, Human Microbiome Project Consortium, et al. 2012. A framework for human microbiome research. *Nature* 486:215–221. <https://doi.org/10.1038/nature11209>.
60. Dirks JAMC, van Liere GAFS, Hoebe CJP, Wolffs P, Dukers-Muijers NHTM. 2019. Genital and anal *Chlamydia trachomatis* bacterial load in concurrently infected women: a cross-sectional study. *Sex Transm Infect* 95:317–321. <https://doi.org/10.1136/sextrans-2018-053678>.
61. Wind CM, Schim van der Loeff MF, Unemo M, Schuurman R, van Dam AP, de Vries HJC. 2016. Time to clearance of *Chlamydia trachomatis* RNA and DNA after treatment in patients coinfecting with *Neisseria gonorrhoeae* – a prospective cohort study. *BMC Infect Dis* 16:554. <https://doi.org/10.1186/s12879-016-1878-3>.
62. van Liere Geneviève AFS, Dukers-Muijers Nicole HTM, Levels L, Hoebe Christian JPA. 2017. High proportion of anorectal *Chlamydia trachomatis* and *Neisseria gonorrhoeae* after routine universal urogenital and anorectal screening in women visiting the sexually transmitted infection clinic. *Clin Infect Dis* 64:1705–1710. <https://doi.org/10.1093/cid/cix243>.
63. Slifirski JB, Vodstrcil LA, Fairley CK, Ong JJ, Chow E, Chen MY, Read T, Bradshaw CS. 2017. *Mycoplasma genitalium* infection in adults reporting sexual contact with infected partners, Australia, 2008–2016. *Emerg Infect Dis* 23:1826–1833. <https://doi.org/10.3201/eid2311.170998>.
64. Fredricks DN. 2011. Molecular methods to describe the spectrum and dynamics of the vaginal microbiota. *Anaerobe* 17:191–195. <https://doi.org/10.1016/j.anaerobe.2011.01.001>.
65. Huang Y-E, Wang Y, He Y, Ji Y, Wang L-P, Sheng H-F, Zhang M, Huang Q-T, Zhang D-J, Wu J-J, Zhong M, Zhou H-W. 2015. Homogeneity of the vaginal microbiome at the cervix, posterior fornix, and vaginal canal in pregnant Chinese women. *Microb Ecol* 69:407–414. <https://doi.org/10.1007/s00248-014-0487-1>.
66. Smith WL, Hedges SR, Mordechai E, Adelson ME, Trama JP, Gygyax SE, Kaunitz AM, Hilbert DW. 2014. Cervical and vaginal flora specimens are highly concordant with respect to bacterial vaginosis-associated organisms and commensal *Lactobacillus* species in women of reproductive age. *J Clin Microbiol* 52:3078–3081. <https://doi.org/10.1128/JCM.00795-14>.
67. Zhang X, Li T, Zhang D, Zong X, Bai H, Bi H, Liu Z. 2021. Distinction between vaginal and cervical microbiota in high-risk human papilloma virus-infected women in China. *BMC Microbiol* 21:90. <https://doi.org/10.1186/s12866-021-02152-y>.
68. Chen C, Song X, Wei W, Zhong H, Dai J, Lan Z, Li F, Yu X, Feng Q, Wang Z, Xie H, Chen X, Zeng C, Wen B, Zeng L, Du H, Tang H, Xu C, Xia Y, Xia H, Yang H, Wang J, Wang J, Madsen L, Brix S, Kristiansen K, Xu X, Li J, Wu R, Jia H. 2017. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. *Nat Commun* 8:875. <https://doi.org/10.1038/s41467-017-00901-0>.
69. Macklaim JM, Fernandes AD, Di Bella JM, Hammond J-A, Reid G, Gloor GB. 2013. Comparative meta-RNA-seq of the vaginal microbiota and differential expression by *Lactobacillus iners* in health and dysbiosis. *Microbiome* 1:12. <https://doi.org/10.1186/2049-2618-1-12>.
70. Doerflinger SY, Throop AL, Herbst-Kralovetz MM. 2014. Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner. *J Infect Dis* 209:1989–1999. <https://doi.org/10.1093/infdis/jiu004>.
71. Rampersaud R, Planet PJ, Randis TM, Kulkarni R, Aguilar JL, Lehrer RI, Ratner AJ. 2011. Inerolysin, a cholesterol-dependent cytolysin produced by *Lactobacillus iners*. *J Bacteriol* 193:1034–1041. <https://doi.org/10.1128/JB.00694-10>.
72. Ravel J, Brotman RM, Gajer P, Ma B, Nandy M, Fadrosch DW, Sakamoto J, Koenig SS, Fu L, Zhou X, Hickey RJ, Schwebke JR, Forney LJ. 2013. Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis. *Microbiome* 1:29. <https://doi.org/10.1186/2049-2618-1-29>.
73. Martínez I, Stegen JC, Maldonado-Gómez MX, Eren MA, Siba PM, Greenhill AR, Walter J. 2015. The gut microbiota of rural Papua New Guineans: composition, diversity patterns, and ecological processes. *Cell Rep* 11:527–538. <https://doi.org/10.1016/j.celrep.2015.03.049>.
74. Greenhill AR, Tsuji H, Ogata K, Natsuhara K, Morita A, Soli K, Larkins J-A, Tadokoro K, Odani S, Baba J, Naito Y, Tomitsuka E, Nomoto K, Siba PM, Horwood PF, Umezaki M. 2015. Characterization of the gut microbiota of Papua New Guineans using reverse transcription quantitative PCR. *PLoS One* 10:e0117427. <https://doi.org/10.1371/journal.pone.0117427>.
75. Knights D, Ward TL, McKinlay CE, Miller H, Gonzalez A, McDonald D, Knight R. 2014. Rethinking “enterotypes”. *Cell Host Microbe* 16:433–437. <https://doi.org/10.1016/j.chom.2014.09.013>.
76. Omsland A, Susanne Sixt B, Horn M, Hackstadt T, Allen PG. 2014. Chlamydial metabolism revisited: interspecies metabolic variability and developmental stage-specific physiologic activities. *FEMS Microbiol Rev* 38: 779–801. <https://doi.org/10.1111/1574-6976.12059>.
77. Bommana S, Somboonna N, Richards G, Tarazkar M, Dean D. 2021. Tryptophan operon diversity reveals evolutionary trends among geographically disparate *Chlamydia trachomatis* ocular and urogenital strains affecting tryptophan repressor and synthase function. *mBio* 12:e00606-21. <https://doi.org/10.1128/mBio.00605-21>.
78. Somboonna N, Ziklo N, Ferrin TE, Suh JH, Dean D, Nacy CA, Ayiar A, Hammerschlag M. 2019. Clinical persistence of *Chlamydia trachomatis* sexually transmitted strains involves novel mutations in the functional  $\alpha\beta\beta\alpha$  tetramer of the tryptophan synthase operon. *mBio* 10:e01464-19. <https://doi.org/10.1128/mBio.01464-19>.
79. Ziklo N, Huston WM, Hocking JS, Timms P. 2016. *Chlamydia trachomatis* genital tract infections: when host immune response and the microbiome

- collide. *Trends Microbiol* 24:750–765. <https://doi.org/10.1016/j.tim.2016.05.007>.
80. Baldewijns S, Sillen M, Palmans I, Vandecruys P, Van Dijck P, Demuyser L. 2021. The role of fatty acid metabolites in vaginal health and disease: application to Candidiasis. *Front Microbiol* 12:705779. <https://doi.org/10.3389/fmicb.2021.705779>.
81. Andrews S. 2010. FastQC: a quality control tool for high throughput sequence data. Babraham Bioinformatics, Cambridge, UK. <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>.
82. Krueger F, James F, Ewels P, Afyounian E, Schuster-Boeckler B. 2021. FelixKrueger/TrimGalore: v0.6.7—DOI via Zenodo (0.6.7). Zenodo, Geneva, Switzerland. <https://zenodo.org/record/5127899#YmpPmujMJD8>.
83. McIver LJ, Abu-Ali G, Franzosa EA, Schwager R, Morgan XC, Waldron L, Segata N, Huttenhower C. 2018. bioBakery: a meta'omic analysis environment. *Bioinformatics* 34:1235–1237. <https://doi.org/10.1093/bioinformatics/btx754>.
84. Truong DT, Franzosa EA, Tickle TL, Scholz M, Weingart G, Pasolli E, Tett A, Huttenhower C, Segata N. 2015. MetaPhlan2 for enhanced metagenomic taxonomic profiling. *Nat Methods* 12:902–903. <https://doi.org/10.1038/nmeth.3589>.
85. McIntyre ABR, Ounit R, Afshinnekoo E, Prill RJ, Hénaff E, Alexander N, Minot SS, Danko D, Foox J, Ahsanuddin S, Tighe S, Hasan NA, Subramanian P, Moffat K, Levy S, Lonardi S, Greenfield N, Colwell RR, Rosen GL, Mason CE. 2017. Comprehensive benchmarking and ensemble approaches for metagenomic classifiers. *Genome Biol* 18:182. <https://doi.org/10.1186/s13059-017-1299-7>.
86. Wood DE, Salzberg SL. 2014. Kraken: ultrafast metagenomic sequence classification using exact alignments. *Genome Biol* 15:R46.
87. Yue JC, Clayton MK. 2005. A similarity measure based on species proportions. *Commun Stat—Theory Methods* 34:2123–2131. <https://doi.org/10.1080/STA-200066418>.
88. R Core Team. 2016. R: a language and environment for statistical computing. R Foundation Statistical Computing, Vienna, Austria.
89. Wickham H. 2016. ggplot2: elegant graphics for data analysis. Springer-Verlag, New York, NY.